Pegaspargase Alternatives Compared
| Pegaspargase | Blincyto | Methotrexate |
|
|---|
| Pegaspargase | Blincyto (blinatumomab) | Methotrexate |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Acute Lymphoblastic Leukemia. Pegaspargase may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Acute Lymphoblastic Leukemia. Blincyto may also be used for purposes not listed in this medication guide. |
Prescription only
Methotrexate may be considered for the treatment of psoriasis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (pJIA), mycosis fungoides, and certain cancers, such as ALL or... View more |
Related suggestions Acute Lymphoblastic Leukemia
|
|||||||||||||||
| More about Pegaspargase | More about Blincyto (blinatumomab) | More about Methotrexate | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Pegaspargase has an average rating of 1.0 out of 10 from a total of 2 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 100% reported a negative effect. |
Blincyto has an average rating of 10.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Methotrexate has an average rating of 6.6 out of 10 from a total of 334 ratings on Drugs.com. 54% of reviewers reported a positive effect, while 23% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
Lower cost generic |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Blincyto prices |
View all Methotrexate prices |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Oncaspar |
N/A |
Jylamvo, Methotrexate LPF Sodium, Otrexup, Rasuvo, Trexall, Xatmep | ||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
137 hours |
2.11 hours |
15 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 516 drugs are known to interact with Pegaspargase:
|
A total of 266 drugs are known to interact with Blincyto:
|
A total of 708 drugs are known to interact with Methotrexate:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
December 03, 2014 |
December 07, 1953 |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
|
||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.